ZLY025 |
Catalog No.GC80882
One-Click Copy Product Info
|
ZLY025 is a potent and orally active CCNK molecular glue degrader with an DC50 of 42.7 nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 3070379-34-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
In Vivo, ZLY025 (10-40 mg/kg; i.g.; once daily for 17 days; ) inhibits tumor growth in BALB/c nude mice bearing A549 xenografts[1]. ZLY025 (200 mg/kg, i.g., once daily for 14 days) shows extremely low subacute toxicity in ICR mice[1].
In Vitro, ZLY025 exhibits broad-spectrum antiproliferative activity against various tumor cell lines including lung cancer, breast cancer, liver cancer, and leukemia, with IC50 values ranging from 0.08 to 2.45 μM[1]. ZLY025 (125-500 nM; 24 h) induces A549 cells apoptosis and G1 phase arrest[1]. ZLY025 (30-1000 nM; 8-24 h) reduces expression of CCNK, CDK12, p-CTD, and BRCA1 in A549 cells[1].
References:
[1]. Liu Y, et al. Discovery of Highly Potent and Orally Available CCNK Molecular Glue Degraders as Broad-Spectrum Antitumor Agents. J Med Chem. 2025;68(21):22689-22714.
| Cas No. | 3070379-34-6 | SDF | |
| Formula | C15H13N3O2S | M.Wt | 299.35 |
| Solubility | DMSO: 5 mg/mL (16.70 mM; Need ultrasonic) | Storage | Store at -20°C |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.3406 mL | 16.7029 mL | 33.4057 mL |
| 5 mM | 668.1 μL | 3.3406 mL | 6.6811 mL |
| 10 mM | 334.1 μL | 1.6703 mL | 3.3406 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)